SNY (Sanofi) FCF Margin % : -2.06% (As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sanofi's Free Cash Flow for the six months ended in Jun. 2024 was $-498 Mil. Sanofi's Revenue for the six months ended in Jun. 2024 was $24,217 Mil. Therefore, Sanofi's FCF Margin % for the quarter that ended in Jun. 2024 was -2.06%.

As of today, Sanofi's current FCF Yield % is 3.41%.

The historical rank and industry rank for Sanofi's FCF Margin % or its related term are showing as below:

SNY' s FCF Margin % Range Over the Past 10 Years
Min: 8.8 Med: 16.67 Max: 21.64
Current: 8.8

During the past 13 years, the highest FCF Margin % of Sanofi was 21.64%. The lowest was 8.80%. And the median was 16.67%.

SNY's FCF Margin % is ranked better than
72.12% of 990 companies
in the Drug Manufacturers industry
Industry Median: 0.79 vs SNY: 8.80

Sanofi FCF Margin % Historical Data

The historical data trend for Sanofi's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi FCF Margin % Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

15.75

14.28

21.64

18.34

15.58

Sanofi Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial															13.71	22.26	12.22	18.48	-2.06

Competitive Comparison of Sanofi's FCF Margin %

For the Drug Manufacturers - General subindustry, Sanofi's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sanofi's FCF Margin % falls into.

Sanofi FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sanofi's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	7888.768	/	50647.764
	=	15.58 %

Sanofi's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-498.385	/	24217.438
	=	-2.06 %

Sanofi FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sanofi's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.